Key Takeaways

• The information gap in California treatment-business acquisitions is usually not fraudulent — it is a mix of the seller’s own compliance blind spots, misremembered history, and features the seller doesn’t consider diligence-material.
• Seven categories account for most of the gap: historical marketing content; paper medical director substance; standing-order vs. patient-specific-order practice; direct patient billing by the LLC; sourcing arrangements for prescription drugs and injectables; historical regulatory contact (Medical Board / BRN / DEA / AG / DHCS / payor); and clinical incidents that never generated formal complaints.
• Each category has a specific diligence pattern that surfaces it. Documentary requests, cross-referencing against public disciplinary databases, site archive review, sample chart review, and candid conversations with the current medical director each play a role.
• The purpose is not adversarial — it is to give both sides an accurate picture of the target so the deal can be structured (or repriced, or walked away from) with informed judgment on both sides.

What Your Seller Isn’t Telling You in a California Treatment Business Acquisition

Most sellers of California treatment businesses are not trying to defraud the buyer. They are trying to close a deal on the target they have built and operated, sometimes for years, sometimes under advice from lawyers and accountants who told them the current structure was fine, sometimes with a genuinely held belief that “wellness” or “cash-pay” or “mobile” or “LLC” was a legitimate compliance framework. Which means the things the seller doesn’t tell the buyer are usually not calculated omissions — they are the things the seller doesn’t know are material, doesn’t remember, or has never treated as diligence-worthy.

Buyer’s counsel’s job is to surface these anyway. This post walks through the seven categories where the gap between “what the seller volunteers” and “what the buyer needs to know” tends to open widest. It is the companion to the ten pre-LOI questions post and to the walk-away analysis post — together they form the diligence toolkit for a non-licensee buyer.

The Seven Gap Categories

1. Historical marketing content the site no longer shows

What the seller volunteers. The current site, the current social media, the current paid ads.

What the seller often doesn’t volunteer. Content that has been on the site for the last three to five years but is no longer live — outcome claims for indications the practice no longer treats; testimonials from patients whose results were atypical; before-and-after imagery with specific claims attached; endorsement content from influencers whose contracts are no longer in force; representations about physician credentials or clinical structure that changed as the practice grew.

Why it matters. California false-advertising exposure under B&P § 17500 and the Unfair Competition Law does not evaporate when the content comes down. Consumer-protection claims can reach back to representations made at the time a patient paid for services. Marketing exposure travels with the target’s operating history and can attach to the buyer through mere-continuation doctrines even in an asset purchase.

How buyer’s counsel surfaces it. Wayback Machine review of the site for the last three to five years; social media archive review (some platforms let a new owner access historical posts); paid-search history through the seller’s ad platforms; influencer contracts for any endorsement content; testimonial and review platform history. The buyer’s counsel should also cross-reference current claims against FDA guidance for any modality-specific representations (HBOT off-label claims, GLP-1 compounded product claims, IV therapy outcome claims).

2. What the medical director actually does day-to-day

What the seller volunteers. “We have a medical director. Here’s the agreement. She’s board-certified in [specialty].”

What the seller often doesn’t volunteer. How many good-faith exams the medical director has personally conducted in the last quarter. How many charts she has reviewed. When she last updated the standardized procedures. Whether she is physically present or immediately available during procedures. Whether she has ever had a call from an injecting RN about a clinical incident. Whether she has other medical director roles at other practices, and how many.

Why it matters. A paper medical director — a physician who signs the paperwork but has minimal actual clinical involvement — is one of the frequent Medical Board and BRN enforcement findings in California treatment-business enforcement. B&P § 2264 exposes the physician to discipline for aiding and abetting the practice of medicine by an unlicensed entity; § 17200 exposes the practice to civil penalties. Buyers who acquire the practice with the same medical director without surfacing the substance of the role inherit both the ongoing operational defect and the historical exposure.

How buyer’s counsel surfaces it. Activity records for the medical director — GFEs conducted, charts reviewed, standardized procedures signature dates, hours logged. A conversation with the medical director directly, ideally without the seller in the room. Cross-reference against the Medical Board’s public license lookup for any disciplinary history and for the physician’s other roles (if the physician is a medical director at a large number of practices, the substance of any one of those roles is worth examining). The medical director’s professional liability coverage — a policy that excludes med spa or IV therapy administration would suggest the physician has not been genuinely engaged with the practice’s clinical operations.

3. Standing-order practice vs. patient-specific-order practice

What the seller volunteers. “We follow our medical director’s protocols.”

What the seller often doesn’t volunteer. Whether the “protocols” are patient-specific orders written after a good-faith exam for each patient, or standing orders that apply to every patient with a broad indication. Whether the RN administering treatment consults the physician on each patient’s plan, or draws from a standing-order binder. Whether the good-faith exam is conducted by a licensed prescriber (physician, NP, or PA) in person or by synchronous video, or by RN intake and rubber-stamp physician sign-off.

Why it matters. The 2026 California GFE standard, reflected in Medical Board and BRN guidance and in practitioner analysis, treats standing orders as an enforcement trigger. Patient-specific orders based on a good-faith exam by a licensed prescriber under B&P § 2242 are the operational baseline. Practices that have been running on standing orders and RN-only intake are operating below the current standard, and the buyer’s post-closing structure will have to rebuild the workflow to meet it.

How buyer’s counsel surfaces it. Sample patient charts (identifying information redacted) for the last six months. The standing-order binder or protocol document, with dates of signature. The GFE workflow walkthrough. Ideally, an observation of the intake process with actual patients (with appropriate consent). The standardized procedures manual under 16 CCR § 1474.

4. Direct patient billing by the LLC or non-physician entity

What the seller volunteers. “The MSO handles administration. Patient billing is straightforward — cards get charged, patients get receipts.”

What the seller often doesn’t volunteer. Which entity is on the merchant processor. Which entity’s name appears on patient billing statements. Which entity’s bank account receives patient payments. Whether patient payments have been flowing to the LLC or non-physician entity that has been operating the practice, rather than to a physician-owned PC that then pays the MSO by invoice against the MSA.

Why it matters. Direct patient billing by an entity not authorized to render medical services is a specific CPOM defect and is treated as evidence of the underlying structural violation under B&P § 17200. It is also one of the operational features regulators can verify without visiting the practice. Practices that have been operating this way have both an ongoing structural defect and a historical exposure that attaches to the entity.

How buyer’s counsel surfaces it. Merchant processor documentation. Sample patient billing statements. The entity name on the practice’s Yelp/Google Business Profile receipt reference. Bank statement review to trace where patient payments actually landed for the last twelve months. The intercompany invoicing between the PC and MSO (if there is one) to confirm the payment flow actually runs PC → MSO by invoice, not patient → MSO → PC.

5. Where the medications and injectables actually come from

What the seller volunteers. “We use standard suppliers.”

What the seller often doesn’t volunteer. The specific supplier list. Whether the practice has been sourcing through prescription-authorized channels tied to the physician-of-record. Whether the injectable products (Botox, dermal fillers, GLP-1 compounded products) have been sourced from gray-market suppliers offering unauthorized wholesale pricing. Whether the compounding pharmacies serving the IV or infusion side of the practice are properly registered under USP 797 and, where applicable, the FDA’s 503A/503B framework. Whether the DEA registration for any controlled substances is current and in the physician-of-record’s name.

Why it matters. Prescription drugs held or administered by a practice have to be procured through prescription-authorized channels. Gray-market injectable suppliers, prescription drugs held without corresponding prescription documentation, and controlled substances held under expired or wrong-name DEA registration are defects the buyer needs to price into the deal. Contamination and adverse-reaction incidents from unauthorized sourcing have prompted enforcement scrutiny nationally.

How buyer’s counsel surfaces it. Supplier list with contact information. Prescription records for any legend drugs held. DEA registration certificate for the physician of record. Inventory reconciliation for the last twelve months. Compounding pharmacy contracts (for IV / infusion practices). For GLP-1 practices, particular attention to sourcing during and after the FDA shortage-list transitions.

6. Regulatory contact the seller doesn’t remember as “material”

What the seller volunteers. “No complaints, no investigations, no problems.”

What the seller often doesn’t volunteer. A Medical Board inquiry that was resolved without discipline three years ago. A BRN investigation of one of the injecting RNs that closed without action. A DEA registration renewal issue that got resolved. A payor audit that resulted in a small recoupment. A DHCS clinic-licensure question that got clarified by phone. An AG office contact that the seller treated as a courtesy call. Any of these that are ongoing but haven’t yet resulted in formal action.

Why it matters. Regulatory contact history is diligence-material even when it didn’t result in formal action. Public disciplinary records don’t capture inquiries that closed without discipline. And ongoing but not-yet-formal matters are exactly the exposure the buyer most wants to know about pre-LOI. The seller’s inclination is often to remember only the matters that generated paperwork; the buyer needs a broader view.

How buyer’s counsel surfaces it. A written diligence request specifically covering “any contact from any regulator, payor, or public complaint mechanism in the last five years — resolved or ongoing, formal or informal, involving the practice or any physician or clinical staff member.” A cross-reference against the Medical Board’s public license lookup for every physician who has been associated with the practice; corresponding BRN verification for RN staff. Bay Legal’s diligence sequence typically also includes a public records request or two where the practice has been in a specific enforcement category — an approach the seller often doesn’t anticipate.

7. Clinical incidents that never generated a formal complaint

What the seller volunteers. “No adverse events.”

What the seller often doesn’t volunteer. A patient reaction to an IV formulation that resolved with treatment but wasn’t reported through a formal system. A hyperbaric chamber event that the staff managed but that wasn’t logged. A Botox complication the practice comped out of. A GLP-1 side-effect pattern the medical director noticed but didn’t escalate. Complaints that came in through Yelp or Google Reviews without generating a formal complaint to the Medical Board or BRN. Refund requests the practice paid to avoid escalation.

Why it matters. Clinical incidents that never generated a formal complaint are still diligence-material for three reasons: (a) some of them may still be within statute-of-limitations for private claims; (b) the pattern of incidents can reveal operational or clinical structure issues the buyer needs to address post-closing; (c) they can inform the buyer’s professional liability tail coverage decisions and the pricing of the buyer’s forward malpractice insurance.

How buyer’s counsel surfaces it. Incident logs, if the practice maintains them. Refund records from the last three years — a refund pattern in a specific service line or with a specific provider is a signal worth exploring. Review-site history including responses to negative reviews. Insurance claims history from the practice’s professional liability carrier. Conversation with the medical director (again, ideally without the seller in the room) about any events the medical director recalls that don’t appear in formal records.

The Framing That Works With Sellers

The purpose of surfacing these gaps is not adversarial. Framed correctly, the diligence is a service to both sides.

The buyer wants to know what the practice actually looks like operationally so the deal can be structured, priced, and closed with informed judgment. The seller wants the deal to close and to survive post-closing without unwind claims. When both sides have an accurate picture of the target — including the historical exposure, the deal documents can allocate that exposure correctly (through reps, warranties, indemnification, escrow, and holdback), the closing transition can address the operational defects, and the post-closing relationship can move forward without surprises.

The framing that works, in almost every diligence conversation, is: “This is a healthcare-specific compliance review. Some of what we ask about is unusual for general M&A diligence, but it maps to a specific set of enforcement patterns California regulators have been active on in 2026. Our job is to structure a deal that survives that environment. Your job is to give us an accurate picture of what we’re acquiring. We are not trying to find reasons to walk — we are trying to give you a deal that closes and stays closed.”

Most sellers respond to that framing well. Sellers who don’t — who resist documentation requests, who evade specific questions, who characterize their prior legal advice in ways their documents contradict, are themselves a diligence finding.

When to Bring Counsel Into the Diligence

Before the LOI is signed. Structuring the diligence to surface the gap categories above is exactly what pre-LOI healthcare counsel does — the general M&A framework does not include these categories, and buyers who rely on a general M&A diligence checklist consistently miss the healthcare-specific issues that end up mattering post-closing.

Bay Legal, PC represents non-licensee buyers of California treatment businesses through pre-LOI structuring counsel, CPOM diligence, and deal documentation. Call (650) 668-8000 or schedule a consultation at baylegal.com/contact.

Frequently Asked Questions

Is the seller trying to hide these things from me?

Usually not intentionally. Most sellers of California treatment businesses have been operating under advice they believed was correct, in an industry where informal practice has often diverged from formal compliance, and they don’t know which of the operational features of their business are diligence-material. The gap between what the seller volunteers and what the buyer needs to know is usually about the seller’s blind spots, not calculated omissions. This does not change the buyer’s need to surface the information; it changes how the buyer frames the conversation.

Should I hire a private investigator or use adversarial diligence tactics?

For most treatment-business acquisitions, no. The information gap is closed through healthcare-specific documentary requests, cross-referencing against public regulatory databases, site archive review, sample chart review, and candid conversation with the current medical director. Adversarial tactics are typically unnecessary and often counterproductive — they poison the seller relationship and don’t produce meaningfully better information. A healthcare-experienced buyer’s counsel using standard diligence tools is what works.

What if I discover material undisclosed exposure after the deal closes?

The recourse depends on the deal documents — reps and warranties, indemnification provisions, escrow or holdback amounts, survival periods, and any specific carve-outs. Well-structured asset purchase agreements for California healthcare acquisitions typically include: specific reps around CPOM compliance, medical director substance, standardized procedures, marketing accuracy, and regulatory contact history; indemnification with a survival period long enough to cover the CPOM statute-of-limitations analogs; and escrow or holdback for meaningful historical exposure. Whether the buyer can recover under those provisions depends on the specific finding and the documents.

How do I have the conversation with the medical director without offending the seller?

Frame the conversation as standard for healthcare acquisitions: “Our diligence framework includes a direct conversation with the medical director because the medical director’s role is central to the practice’s clinical structure. We will do this in every California treatment-business acquisition — it’s not specific to your practice.” Most sellers accept this framing. Sellers who resist are themselves providing information, the more the seller resists direct contact with the medical director, the more likely there is something the seller doesn’t want surfaced.

How does this list interact with the pre-LOI ten questions post?

The pre-LOI ten questions post is the buyer’s outreach: what the buyer asks the seller to surface. This post is the buyer’s counsel’s independent diligence: what the buyer’s counsel does to surface information the seller doesn’t volunteer. Together they close most of the information gap that healthcare-specific diligence needs to address. The third post in the trio, the walk-away analysis, addresses what to do when the diligence surfaces findings the deal cannot survive.

Talk to a California Healthcare Acquisition Attorney

Bay Legal, PC represents non-licensee buyers of California treatment businesses through pre-LOI structuring counsel, CPOM diligence, and deal documentation. If you are evaluating a target and want to close the information gap between what the seller volunteers and what your deal needs to survive, call (650) 668-8000 or schedule a consultation at baylegal.com/contact.